Allergic rhinitis
Conditions
Interventions
None listed
Sponsors
Doi Ohashi Katsuyo
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. At least two 6-SQ HDM SLIT-tablets (10,000 JAU) prescriptions during the first FU year 2. Continuous enrollment (no gaps in insurance time-defined by days) for 12 months before the index event (in the pre-index period) 3. Continuous enrollment (no gaps in insurance time-defined by days) for at least 12 months after the index event (in the post-index period) For the control cohort, the same inclusion criteria will apply, with the exception of inclusion criterion 1.
Exclusion criteria
Exclusion criteria: Other AIT without JCP SLIT tablets/drops prescription and prescriptions of any biologics 12 months before the index event (in the pre-index period)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of patients with at least one symptom-relieving AR prescriptions by each FU year Number of total symptom-relieving AR prescriptions by each FU year Change in total number of symptom-relieving AR prescriptions from the pre-index year (baseline) to each FU year | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.Number of symptom-relieving AR prescriptions per drug class by each FU year and change in total number of symptom-relieving AR prescriptions per drug class from the pre-index year (baseline) to each FU year 2.Healthcare resource utilization (HRU) 3.Anaphylaxis shock within 7 days related to 2 and 6-SQ HDM SLIT-tablets initiation: -Number of patients with anaphylaxis shock -Number of events of anaphylaxis shock 4.Number of patients with allergy-related comorbidities and number of comorbidities 5.Medical costs | — |
Contacts
Public ContactHiroki Matsuhara
Torii Pharmaceutical Co., Ltd.
Outcome results
None listed